6 news items
Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model
ATOS
28 May 24
program, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, and the potential safety and tolerability profile of (Z
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
ATOS
13 May 24
completed five-years of successful treatment. The patient remains cancer-free and reported no significant safety or tolerability issues over the course
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
ATOS
29 Apr 24
, and the potential safety and tolerability profile of (Z)-endoxifen, to differ materially from those projected or anticipated, including risks
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
ATOS
15 Apr 24
cancer prevention and treatment agent, and the potential safety and tolerability profile of (Z)-endoxifen, to differ materially from those projected
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
ATOS
9 Apr 24
" or the "Company") today announced promising safety and efficacy data from the Company's Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial
sruk jtb8fur
ATOS
1 Apr 24
Meeting – safety and efficacy data from the 40mg pharmacokinetic run-in cohort of the ongoing Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn
- Prev
- 1
- Next